Xilio reports Q1 net loss $13.3M, cash $89.1M; AbbVie deal provides $52M upfront

Xilio Therapeutics, Inc.

2025-Q1 EPS reported -$0.18 revenue$2,930,000

Net loss $13.3M for Q1 2025, vs $17.2M Q1 2024.
Cash $89.1M as of Mar 31, 2025, up from $55.3M at Dec 31, 2024, driven by $52M AbbVie upfront.
R&D expenses $8.3M (down from $10.4M); G&A $8.5M (up from $6.1M) year-over-year.
Updated Phase 2 data for vilastobart + atezolizumab in MSS CRC to be presented at ASCO 2025 (abstract 3553).
First development candidates for masked T cell engagers (PSMA, CLDN18.2, STEAP1) expected H2 2025–H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.